Recent evidence indicates that IL-20 is a therapeutic target in various cancers, including breast cancer, and that an anti-IL-20 monoclonal antibody has therapeutic potential for alleviating inflammation and osteolysis associated with tumor progression [9, 13, 15, 16]. The gene discussed is IL20; the disease is breast cancer.